SLKovid: Seroprevalence of SARS-CoV-2 in employees of a clinic with COVID-centre (COVID-19)

SLKovid: Seroprevalence of SARS-CoV-2 in employees of a clinic with COVID-centre (COVID-19) - SLKovid

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00022226

Enrollment

5000

Registered

2020-07-06

Start date

2020-07-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-COV-2-INFECTION COVID-19

Interventions

Group 1: Serologic antibody test of SARS-CoV-2 antibodies

Eligibility

Sex/Gender

All

Age

14 Years to 99 Years

Inclusion criteria

Inclusion criteria: Employees of SLK-Kliniken Heilbronn GmbH

Exclusion criteria

Exclusion criteria: No consent regarding study or parts of the study.

Design outcomes

Primary

Measure	Time frame
Serum analyses of antibodies against SARS-CoV-2 at 0 (if positive, additionalley at 3, 6 and 12 months) plus questionnaire	—

Secondary

Measure	Time frame
Characterisation of the immune answer to SARS-CoV-2 Comparison of several commercially available CE-certified test Systems Confirmation by neutralisation test Analysis of infection rate by exposition and field of work Evaluation of risk factors and prevention factors	—

Countries

Germany

Contacts

Public ContactUwe Martens

SLK-Kliniken Heilbronn GmbH

josef.huber@slk-kliniken.de07131-49-28715

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026